Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Type 2 Diabetes
Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler
This is an open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of Technosphere Insulin (TI) Inhalation Powder in combination with insulin glargine versus insulin aspart in combination with…
- Trial name
- NCT01196104
- Testing
- Technosphere® Insulin Inhalation Powder, Insulin Aspart, Insulin Glargine
- Where
- 29 sites in United States
- Volunteers
- 39 people
- Sponsor
- Mannkind Corporation
Type 2 Diabetes
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs
The study is being conducted to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with oral antidiabetic drugs compared to insulin Glargine QD for 26+26 weeks.
- Trial name
- NCT05699408
- Testing
- INS068 injection, Insulin Glargine
- Where
- China
- Volunteers
- 513 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type2 Diabetes Mellitus
A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
The objectives of the study is to evaluate the efficacy, safety, and dose of DS-8500a compared with placebo in patients with type 2 diabetes mellitus.
- Trial name
- NCT02628392
- Testing
- DS-8500a, Sitagliptin
- Where
- Japan
- Volunteers
- 368 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Type 2 Diabetes Mellitus, Healthy Volunteers
The Effects of Short-time High-intensity Interval Training on Tissue Glucose and Fat Metabolism in Healthy Subjects and Patients With Type 2 Diabetes
The objectives of this study are to investigate the effects of short-time high-intensity interval training on tissue glucose and fat metabolism in healthy lean subjects and type 2 diabetic patients using modern and noninvasive…
- Trial name
- HITPET (NCT01344928)
- Testing
- HIT exercise intervention, Aerobic exercise intervention
- Where
- Finland
- Volunteers
- healthy volunteers welcome
- Sponsor
- Turku University Hospital
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
- Trial name
- PIONEER 2 (NCT02863328)
- Testing
- semaglutide, empagliflozin
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 822 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effect of canagliflozin on post-meal glucose blood levels in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01381887
- Testing
- Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes
A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, active-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets compared with dapagliflozin in adults with type 2 diabetes…
- Trial name
- NCT07082114
- Testing
- HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes
Pharmacokinetic and Safety Studies of HRS-7535 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
The study is being conducted to evaluate and compare the pharmacokinetics of HRS-7535 tablets in subjects with moderate renal insufficiency and healthy subjects.
- Trial name
- NCT06132204
- Testing
- HRS-7535 Tablets
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Type 2 Diabetes
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
This study is a multicenter, randomized, open-label, parallel-group, phase 3 clinical trial aimed at evaluating the efficacy and safety of HDM1005 versus active comparator in subjects with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT07417306
- Testing
- HDM1005 1, HDM1005 2, Mazdutide
- Where
- China
- Volunteers
- 912 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Type 2 Diabetes
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
To evaluate the similarity of the efficacy and safety of semaglutide injection (QLG2065) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.
- Trial name
- NCT05950516
- Testing
- Semaglutide, Semaglutide Pen Injector [Ozempic]
- Where
- China
- Volunteers
- 478 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
A First-in-Human Study of LY2409021 in Healthy Participants and Participants With Type 2 Diabetes
The main purpose of this study is to determine the safety of LY2409021 in healthy participants and participants with diabetes. The study drug is given as single oral doses.
- Trial name
- NCT01606371
- Testing
- LY2409021
- Where
- Singapore
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Metabolic Syndrome
Protein, Amino Acids & Insulin & Glucagon Secretion in Humans
The purpose of this study is to determine the effect of various foods and/or food substances such as fats or proteins on the blood glucose and insulin concentrations in people with and without type 2 diabetes.
- Trial name
- NCT01471509
- Testing
- water, glucose with or without amino acid
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Type 2 Diabetes Mellitus
Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM
This study will evaluate how EFB0027 and EFB0026 behave in subjects with type 2 diabetes mellitus. In addition, this study will compare the effects of EFB0027 and EFB0026 on circulating concentrations of glucose and…
- Trial name
- NCT01677299
- Testing
- EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Diabetes, Diabetes Mellitus, Type 1
Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate steady state pharmacokinetics of biphasic insulin aspart 30 and biphasic insulin aspart 70 in subjects with type 1 diabetes.
- Trial name
- NCT01524809
- Testing
- biphasic insulin aspart 30, biphasic insulin aspart 70
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
This is a dose-escalating study in patients with Type 2 diabetes on metformin. Participants will receive an investigational product or placebo for 28 days.
- Trial name
- NCT03538743
- Testing
- PF-06882961
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)
This study compares insulin icodec (a new insulin taken once a week) to insulin glargine (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 4 (NCT04880850)
- Testing
- Insulin icodec, Insulin glargine, Insulin aspart
- Where
- 116 sites in United States, Belgium and 7 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Obesity
Registry Observing EndoBarrier® Treatment Outcomes in Subjects With Type 2 Diabetes and/or Obesity
The purpose of the registry was to observe the safety and effectiveness outcomes for subjects treated with the EndoBarrier in the post market setting where the product had Conformité Européene (CE mark) regulatory approval and in…
- Trial name
- NCT03072901
- Testing
- EndoBarrier Gastrointestinal Liner
- Volunteers
- 244 people
- Sponsor
- Morphic Medical Inc.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.
- Trial name
- PIONEER 1 (NCT02906930)
- Testing
- semaglutide
- Where
- 105 sites in United States, Algeria and 9 more
- Volunteers
- 703 people
- Sponsor
- Novo Nordisk A/S
Patients
Drug Interaction Study Between Dorzagliatin and Sitagliptin
This is a Phase 1, open-label, sequential, multiple-dose, drug interaction study of glucokinase activator dorzagliatin and sitagliptin in subjects with T2DM.
- Trial name
- NCT03790839
- Testing
- Sitagliptin, Dorzagliatin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Hua Medicine Limited
Fractures, Bone, Type II Diabetes
Fracture Risk With Thiazolidinediones
Treatment with thiazolidinediones (TZD) has recently been reported to possibly increase the risk of fractures in a randomized trial exploring the efficacy of rosiglitazone (RSG), metformin, or glyburide encompassing 4360 patients…
- Trial name
- NCT01055223
- Testing
- TZD only (RSG or PIO or troglitazone), TZD + spironolactone, TZD + amiloride
- Volunteers
- 98,483 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.